Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Completed Phase 3 Interventional Results available

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

NCT02352363
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 30, 2026, 4:12 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women

NCT00611104
View directory record Official record
Conditions
Breast Cancer
Interventions
standardized freeze-dried table grape powder, laboratory biomarker analysis, pharmacological study
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 4 Interventional Results available

Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients

NCT03781089
View directory record Official record
Conditions
Hyperkalemia, End Stage Renal Disease
Interventions
Patiromer Oral Powder Product
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 30, 2026, 4:12 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Feasibility of a Novel Technique for Pilonidal Wound Healing

NCT02330159
View directory record Official record
Conditions
Pilonidal Disease, Pilonidal Cyst, Pilonidal Sinus
Interventions
Novel Wound Healing Protocol
Procedure
Lead sponsor
Southeast Clinical Research Associates, Houston, Texas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 30, 2026, 4:12 PM EDT
Not listed Not applicable Interventional

Zypan Functional Dyspepsia

NCT06320379
View directory record Official record
Conditions
Dyspepsia
Interventions
Zypan, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

NCT01396161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Repeatability and Response Study of Absorptive Clearance Scans

NCT01887197
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Absorptive clearance scan, inhaled hypertonic saline (7%), mannitol inhalation powder
Other · Drug
Lead sponsor
Tim Corcoran
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

NCT06429059
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
Astaxanthin, Protandim, Melatonin, MitoQ
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

NCT01537497
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

NCT03761979
View directory record Official record
Conditions
Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
Interventions
Strontium L-lactate
Dietary Supplement
Lead sponsor
BioLink Life Sciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

NCT01147744
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 30, 2026, 4:12 PM EDT
Not listed Phase 1Phase 2 Interventional

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

NCT02825836
View directory record Official record
Conditions
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
Interventions
TL-895, Navtemadlin
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 30, 2026, 4:12 PM EDT
Terminated Phase 3 Interventional Results available

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

NCT03219164
View directory record Official record
Conditions
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Months to 18 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single Group Study to Evaluate the Efficacy of Bye Bye Bloat Capsules in Relieving Bloating and Promoting Healthy Digestion.

NCT06516744
View directory record Official record
Conditions
Digestive Health, Digestion
Interventions
Bye Bye Bloat Capsules
Dietary Supplement
Lead sponsor
Love Wellness
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Active, not recruiting Phase 2 Interventional

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

NCT06504446
View directory record Official record
Conditions
Refractory or Unexplained Chronic Cough
Interventions
NOC-110, Placebo
Drug · Other
Lead sponsor
Nocion Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
68
States / cities
Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05954988
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
LTI-03, Placebo
Drug
Lead sponsor
Rein Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults

NCT02017405
View directory record Official record
Conditions
Healthy
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Matching Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cary, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01119950
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily, NVA237 50.0 µg once daily, NVA237 25.0 µg twice daily, NVA237 100.0 µg once daily, NVA237 50.0 µg twice daily, Placebo to NVA237 once daily
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Anniston, Alabama • San Diego, California • Torrance, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Theanine and Caffeine on Neurophysiology of Attention

NCT02770105
View directory record Official record
Conditions
L-theanine
Interventions
Theanine, Caffeine, Theanine-Caffeine Combination, Placebo
Other
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL

NCT00801853
View directory record Official record
Conditions
Asthma
Interventions
Aerovant, placebo
Drug · Other
Lead sponsor
Aerovance, Inc.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Mobile, Alabama • Scottsdale, Arizona • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

NCT04010539
View directory record Official record
Conditions
Gonorrhea
Interventions
Gepotidacin, Ceftriaxone, Azithromycin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

NCT05021341
View directory record Official record
Conditions
Glycemia
Interventions
Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 30, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

NCT01710020
View directory record Official record
Conditions
End-Stage Renal Disease, Hemodialysis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Oct 30, 2026, 4:12 PM EDT